Tolstrup 2020.

Study characteristics
Methods	Randomised trial, Denmark.
Participants	146 patients with multiple myeloma receiving immunotherapy.
Interventions	Symptom report using the PRO‐CTCAE with clinician feedback versus usual care.    Intervention features Multiple complex feedback (multiple PROMs at multiple times)  PROM(s) used as intervention: Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Event (PRO‐CTCAE)  Constructs measured: Symptoms Instrument categories/domains: Generic, Domain/Disease specific (mental health)   Administration features Where PROMs administered: Unclear How administered: Self‐administered Format of PROMs questionnaire(s): Electronic   Feedback features Format of PROMs feedback: Unclear How often information fed back: Patients reported symptoms weekly but not clear if they were also fed back weekly Who information fed back to: Clinicians Information fed back: Unclear
Outcomes	Main outcome: number of Grade 3 or 4 adverse events assessed by the Common Terminology for Cancer Adverse Events.
Notes	The study was funded by the Danish Cancer Society.  The study period was not reported. Conflicts of interest were not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information.
Allocation concealment (selection bias)	Unclear risk	Insufficient information.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded by nature of intervention.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information.
Baseline outcome measurements similar	Low risk	Baseline outcome measurements are similar.
Baseline characteristics similar	Unclear risk	Baseline characteristics are similar. Statistical tests conducted.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information.
Was study protected against contamination	High risk	Single‐centre study. Clinicians can treat patients in intervention and control group.
Selective reporting (reporting bias)	Low risk	Pre‐publication information available.